文献詳細
総説
文献概要
薬事法に基づき自己培養骨髄間葉系幹細胞を医薬品(細胞生物製剤)として実用化するべく,医師主導治験を実施している。これまで,前臨床試験(GLP試験)を完了し,GMP(good manufacturing practice)で細胞製剤(治験薬)を製造し,2013年3月より医師主導治験(第III相,二重盲検無作為化試験,検証的試験)を医薬品承認審査調和国際会議のgood clinical practice基準に基づいて実施中である。本稿では認知機能向上の可能性について言及する。
参考文献
1) Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, et al: Intravenous administration of auto-serum expanded autologous mesenchymal stem cells derived from bone marrow into stroke patients. Brain 134: 1790-1807, 2011
2) Honmou O, Onodera R, Sasaki M, Waxman SG, Kocsis JD: Mesenchymal stem cells: therapeutic outlook for stroke. Trends Mol Med 18: 292-297, 2012
3) Suzuki J, Sasaki M, Harada K, Bando M, Kataoka Y, et al: Bilateral cortical hyperactivity detected by fMRI associates with improved motor function following intravenous infusion of mesenchymal stem cells in a rat stroke model. Brain Res 1497: 15-22, 2013
4) Zheng W, Honmou O, Harada K, Suzuki J, Liu H, et al: Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res 1310: 8-16, 2009
5) Osaka M, Honmou O, Murakami T, Nonaka T, Houkin K, et al: Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res 1343: 226-235, 2010
6) Inden M, Takata K, Nishimura K, Kitamura Y, Ashihara E, et al: Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice. J Neurosci Res 91: 62-72, 2013
7) Song CH, Honmou O, Ohsawa N, Nakamura K, Hamada H, et al: The effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prion. J Virol 83: 5918-5927, 2009
8) Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, et al: Anti-tumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11: 1155-1164, 2004
掲載誌情報